Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Antiemetic prophylaxis in patients undergoing hematopoietic stem cell transplantation: a multicenter survey of the Gruppo Italiano Trapianto Midollo Osseo (GITMO) transplant programs.
Pastore D, Bruno B, Carluccio P, De Candia MS, Mammoliti S, Borghero C, Chierichini A, Pavan F, Casini M, Pini M, Nassi L, Greco R, Tambaro FP, Stefanoni P, Console G, Marchesi F, Facchini L, Mussetti A, Cimminiello M, Saglio F, Vincenti D, Falcioni S, Chiusolo P, Olivieri J, Natale A, Faraci M, Cesaro S, Marotta S, Proia A, Donnini I, Caravelli D, Zuffa E, Iori AP, Soncini E, Bozzoli V, Pisapia G, Scalone R, Villani O, Prete A, Ferrari A, Menconi M, Mancini G, Gigli F, Gargiulo G, Bruno B, Patriarca F, Bonifazi F. Pastore D, et al. Among authors: villani o. Ann Hematol. 2020 Apr;99(4):867-875. doi: 10.1007/s00277-020-03945-3. Epub 2020 Feb 8. Ann Hematol. 2020. PMID: 32036421 Free article.
Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study).
Musto P, Simeon V, Cascavilla N, Falcone A, Petrucci MT, Cesini L, Di Raimondo F, Conticello C, Ria R, Catalano L, Salvatore D, Mastrullo L, Gagliardi A, Villani O, Pietrantuono G, D'Arena G, Mansueto G, Bringhen S, Genuardi M, Di Renzo N, Reddiconto G, Fragasso A, Caravita T, Scapicchio D, Marziano G, Boccadoro M, Mangiacavalli S, Corso A. Musto P, et al. Among authors: villani o. Ann Hematol. 2019 Feb;98(2):361-367. doi: 10.1007/s00277-018-3524-1. Epub 2018 Oct 23. Ann Hematol. 2019. PMID: 30353388
A shorter time to the first treatment may be predicted by the absolute number of regulatory T-cells in patients with Rai stage 0 chronic lymphocytic leukemia.
D'Arena G, D'Auria F, Simeon V, Laurenti L, Deaglio S, Mansueto G, Del Principe MI, Statuto T, Pietrantuono G, Guariglia R, Innocenti I, Martorelli MC, Villani O, De Feo V, Del Poeta G, Musto P. D'Arena G, et al. Among authors: villani o. Am J Hematol. 2012 Jun;87(6):628-31. doi: 10.1002/ajh.23170. Epub 2012 Mar 28. Am J Hematol. 2012. PMID: 22460620 Free article.
Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party.
D'Arena G, Valentini CG, Pietrantuono G, Guariglia R, Martorelli MC, Mansueto G, Villani O, Onofrillo D, Falcone A, Specchia G, Semenzato G, Di Renzo N, Mastrullo L, Venditti A, Ferrara F, Palumbo A, Pagano L, Musto P. D'Arena G, et al. Among authors: villani o. Ann Oncol. 2012 Jun;23(6):1499-502. doi: 10.1093/annonc/mdr480. Epub 2011 Oct 29. Ann Oncol. 2012. PMID: 22039089 Free article.
Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie EMatologiche dell'Adulto Multiple Myeloma Working Party study.
Musto P, Simeon V, Grossi A, Gay F, Bringhen S, Larocca A, Guariglia R, Pietrantuono G, Villani O, D'Arena G, Cuomo C, Musto C, Morabito F, Petrucci MT, Offidani M, Zamagni E, Tacchetti P, Conticello C, Milone G, Palumbo A, Cavo M, Boccadoro M. Musto P, et al. Among authors: villani o. Stem Cell Res Ther. 2015 Apr 17;6(1):64. doi: 10.1186/s13287-015-0033-1. Stem Cell Res Ther. 2015. PMID: 25889496 Free PMC article.
A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma.
Larocca A, Bringhen S, Petrucci MT, Oliva S, Falcone AP, Caravita T, Villani O, Benevolo G, Liberati AM, Morabito F, Montefusco V, Passera R, De Rosa L, Omedé P, Vincelli ID, Spada S, Carella AM, Ponticelli E, Derudas D, Genuardi M, Guglielmelli T, Nozzoli C, Aghemo E, De Paoli L, Conticello C, Musolino C, Offidani M, Boccadoro M, Sonneveld P, Palumbo A. Larocca A, et al. Among authors: villani o. Leukemia. 2016 Jun;30(6):1320-6. doi: 10.1038/leu.2016.36. Epub 2016 Feb 22. Leukemia. 2016. PMID: 26898189 Free article. Clinical Trial.
An urologic face of chronic lymphocytic leukemia: sequential prostatic and penis localization.
D'Arena G, Guariglia R, Villani O, Martorelli MC, Pietrantuono G, Mansueto G, Patitucci G, Imbriani E, Masciandaro T, Borgia L, Vita G, D'Auria F, Statuto T, Musto P. D'Arena G, et al. Among authors: villani o. Mediterr J Hematol Infect Dis. 2013;5(1):e2013008. doi: 10.4084/MJHID.2013.008. Epub 2013 Jan 2. Mediterr J Hematol Infect Dis. 2013. PMID: 23350021 Free PMC article.
Peg-filgrastim versus filgrastim after autologous stem cell tranplantation: case-control study in patients with multiple myeloma and review of the literature.
Musto P, Scalzulli PR, Terruzzi E, Rossini F, Iacopino P, Messina G, Guariglia R, Pietrantuono G, Villani O, D'Auria F, Falcone A, Sanpaolo G, Valvano MR, Pogliani EM, Morabito F. Musto P, et al. Among authors: villani o. Leuk Res. 2007 Nov;31(11):1487-93. doi: 10.1016/j.leukres.2007.01.008. Epub 2007 Feb 23. Leuk Res. 2007. PMID: 17320951
Azacitidine for the treatment of lower risk myelodysplastic syndromes : a retrospective study of 74 patients enrolled in an Italian named patient program.
Musto P, Maurillo L, Spagnoli A, Gozzini A, Rivellini F, Lunghi M, Villani O, Aloe-Spiriti MA, Venditti A, Santini V; Ad Hoc Italian Cooperative Study Group on Azacitidine in Myelodysplastic Syndromes Acute Leukemias. Musto P, et al. Among authors: villani o. Cancer. 2010 Mar 15;116(6):1485-94. doi: 10.1002/cncr.24894. Cancer. 2010. PMID: 20151429 Free article.
Epha3 acts as proangiogenic factor in multiple myeloma.
Caivano A, La Rocca F, Laurenzana I, Annese T, Tamma R, Famigliari U, Simeon V, Trino S, De Luca L, Villani O, Berardi S, Basile A, Vacca A, Saglio G, Del Vecchio L, Musto P, Cilloni D. Caivano A, et al. Among authors: villani o. Oncotarget. 2017 May 23;8(21):34298-34309. doi: 10.18632/oncotarget.16100. Oncotarget. 2017. PMID: 28415715 Free PMC article.
44 results